The funding, totaling USD 4.8m, will support a series of scientific collaborations between AbCellera and Gates Foundation-funded scientists working on the prevention and treatment of high-priority infectious diseases.
The target diseases including HIV, malaria, and tuberculosis infect hundreds of millions of people annually and disproportionately impact developing countries.
Research projects will benefit from AbCellera's industry-leading capabilities in human antibody discovery and immune repertoire profiling to accelerate the development of vaccines and antibody-based treatments for use in global health.
This is the second collaboration between the two organizations.
In 2017, AbCellera worked with the Gates Foundation on the discovery of high-affinity monoclonal antibodies against 10 biomarkers associated with Mycobacterium tuberculosis (Mtb) infection, the bacteria responsible for tuberculosis. The resulting antibodies were instrumental in the successful development of high-sensitivity diagnostic tests.
The collaborations funded under the present agreement will benefit from AbCellera's new technology capabilities for deep profiling of antibody responses.
In August 2018, AbCellera announced the acquisition of Lineage Biosciences, a spinout company that pioneered the use of next-generation sequencing technology (Rep-Seq) to capture the full diversity of antibodies generated by natural immune responses.
Rep-Seq complements the unique functional information obtained from AbCellera's single-cell discovery platform, increasing the diversity of antibodies identified and enabling a more rational vaccine design.
AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies.
AbCellera's single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a unique combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation.
Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of lead antibodies from any species, including humans.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial